We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 445

Aerospace and Defense Series: Trump AdministrationPotential for Increased Antitrust Leniency for Vertical Transactions in the Defense Industry
  • McDermott Will & Emery
  • USA
  • December 1 2016

President-elect Donald Trump has called for a dramatic increase in defense spending including purchases of new ships and warplanes as well as the


Merger control: gun jumping goes global
  • McDermott Will & Emery
  • European Union, USA
  • June 28 2010

Broadly defined, "gun jumping" refers to unlawful premerger coordination between the parties to an M&A transaction


International News: Focus on International Dispute Resolution
  • McDermott Will & Emery
  • Chile, China, European Union, France, USA
  • December 1 2016

In October 2016, the European Commission launched a public consultation to


How to (legally) keep competitors from poaching your key employees: antitrust law and non-poachingnon-solicitation agreements
  • McDermott Will & Emery
  • USA
  • August 16 2013

How can a company legally protect its valuable interests in key employees, when a competitor can just swoop in with a more attractive employment


Second Circuit: No Valid Sherman Act Claim Where Citizen Petition Denied Contemporaneously with ANDA Approval
  • McDermott Will & Emery
  • USA
  • November 11 2016

The US Court of Appeals for the Second Circuit held that a pharmaceutical manufacturer failed to state a Sherman Act Section Two claim because the


Massachusetts Court Weighs in on Product Hopping Allegations and Reverse Payment Standing
  • McDermott Will & Emery
  • USA
  • November 11 2016

Addressing a motion to dismiss a bevy of antitrust allegations, the US District Court for the District of Massachusetts held that a class of


Northern District of California Dismisses Claims that Gilead Violated the Antitrust Laws in Seeking to Protect its Position on HIV Drug
  • McDermott Will & Emery
  • USA
  • November 11 2016

Ruling on a motion to dismiss, the US District Court for the Northern District of California dismissed AIDS Healthcare's antitrust claims alleging


Second Circuit Affirms Dismissal of Sham Citizen Petition Claim, Summary Judgment on False Advertising Claims
  • McDermott Will & Emery
  • USA
  • June 28 2016

Addressing Sherman Act and Lanham Act claims arising out of an Abbreviated New Drug Application (ANDA), the US Court of Appeals for the Second


Judge Merrick Garland’s Antitrust Past: A Brief Summary
  • McDermott Will & Emery
  • USA
  • March 23 2016

Since President Obama announced Judge Merrick Garland’s nomination to the Supreme Court of the United States last Wednesday, March 16, 2016, many


US and EU Requirements for Pre-Merger Notification of an Acquisition of a Minority Shareholding Interest
  • McDermott Will & Emery
  • European Union, USA
  • August 8 2016

In May, the Federal Trade Commission (FTC) required Hikma Pharmaceuticals PLC to divest its 23 percent interest in Unimark Remedies, Ltd. and its US